Cendakimab fell short of the bar. The antibody hits IL-13, one of the interleukins targeted by Regeneron and Sanofi’s ...

Sanofi in partnership with Regeneron to present 24 abstracts across approved and investigational medicines at AAAAI Annual Meeting in San Diego: Paris Friday, February 7, 2025, 12 ...

Enrollment of Part A completed ahead of schedule and exceeded enrollment target with 123 patients enrolledPart A 16-week proof-of-concept data ...

Dupixent achieved over €13 billion in sales, growing 16% in Q4, with strong performance across geographies and indications.

This combination study is designed to evaluate the safety, PK, PD and efficacy against DUPIXENT in patients with ... a Phase 2 trial in EoE and plans to further evaluate opportunities to develop ...

This combination study is designed to evaluate the safety, PK, PD and efficacy against DUPIXENT in patients with ... a Phase 2 trial in EoE and plans to further evaluate opportunities to develop ...

According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent ...

Dupixent, or Dupilumab, is an FDA-approved monoclonal antibody for the treatment of eosinophilic esophagitis, or EoE, due to esophageal inflammation. It works on the mechanism of inhibiting IL-4 and ...

SNY misses Q4 earnings and sales estimates. It expects earnings growth to rebound in 2025. It plans to buy back shares worth 5 billion euro in 2025.